Back to top
more

Vaccinex (VCNX)

(Delayed Data from NSDQ)

$5.83 USD

5.83
12,341

-0.10 (-1.70%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $6.19 +0.36 (6.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech

Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech

Sanghamitra Saha headshot

Bet on Rising P/E With These 5 Top-Ranked Stocks

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Implied Volatility Surging for Vaccinex (VCNX) Stock Options

Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates

Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

Bet on Rising Price-to-Earnings With 5 Top Stocks

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1%

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Vaccinex Inc (VCNX) Reports Q1 Loss, Lags Revenue Estimates

Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vaccinex Inc (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.